Neuigkeiten & Ereignisse
Wir laden unsere Kunden und Partner die Updates von ARS-Aktivitäten sowie Nachrichten zu ausgewählten Medikamenten und biologischen Entwicklungen zu verfolgen. Machen Sie gerne einen Termin für ein Meeting mit uns während der Life Science Veranstaltungen, auf denen wir vertreten sind, um potenzielle und aktuelle Projekte persönlich und im Detail zu diskutieren.
ARS PharmRussia gets a new Client that is one of the top biopharmaceutical companies worldwide. ARS team won a tender to conduct a bioequivalence study of an oncology generic drug in Russia. This will be the first project with this Partner. ARS reveals the current challenges and opportunities of a foreign drug registration in Russia. The article posted should be very helpful for the overseas drug developers and manufacturers. ARS congratulates its Partners with the upcoming holidays and wishes all prosperity and good luck in 2018. ARS starts collaboration with one of the leading pharmaceutical companies from the Middle East. ARS hopes the first bioequivalence clinical study project is just the start of the long-term strategic partnership. ARS signed a contract with an Asian Sponsor to conduct a Phase III efficacy and safety clinical study in patients with stomatitis and gingivitis in Russia. ARS will be responsible for the drug’s registration as well. In October 2017, ARS business development director and CEO participated in the biggest pharmaceutical industry event devoted to generics and bio-analogues. Since April through September 2017, ARS registered a number of generic drugs (Montelukast, Nitrofurantoin, Tranexamic Acid, Torasemide, Dorzolamide, Iohexol, Clopidogrel, etc.) as well as successfully did several renewals (Simvastatin, Glucosamine + Chondroitin Sulphate + Vitamin E, Moxifloxacin, Lisinopril, Temozolomide, Piperacillin + Tazobactam, Clarithromycin, Ceftazidime, and Perindopril) for Indian, Pakistani, Russian, and UK pharmaceutical companies. ARS signed an agreement for marketing authorization of Italian dietary supplements as well as medicines to treat metabolic diseases. ARS signed a contract with an Austrian company to support in GMP inspection application to the Russian Ministry of Industry and Trade. ARS has also taken responsibilities for variations and renewal. 